Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy – a retrospective cohort study
There is an increased incidence of gastroparesis among individuals with obesity without T2D who are using semaglutide as compared with bupropion-naltrexone and sleeve gastrectomy. Understanding these potential side effects, though rare, may help guide personalised treatment regimens.
Authors
- Chino Aneke-Nash (ORCID: https://orcid.org/0000-0002-6372-2428)
- Elizabeth Wall‐Wieler (ORCID: https://orcid.org/0000-0003-2480-8875)
- Kay S. Hung (ORCID: https://orcid.org/0009-0001-0724-0379)
- Feibi Zheng (ORCID: https://orcid.org/0000-0001-7590-5566)
- Reem Z. Sharaiha (ORCID: https://orcid.org/0000-0002-3235-6904)
Institutions
- Baylor College of Medicine (US)
- Cornell University (US)
- Intuitive Surgical (Switzerland) (CH)
- Stanford Medicine (US)
- Intuitive Surgical (United States) (US)
- Intuit (United States) (US)
- Stanford University (US)
Publication Details
- Journal
- BMJ Open Gastroenterology
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/bmjgast-2024-001704
- Citations
- 4
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.18
Funders
- Intuitive Surgical